Výsledky vyhledávání - "Emily Schlosnagle"

Abstract P6-15-02: Automated tissue dissection of dermal lymphatic emboli in inflammatory breast cancer enhances accuracy of transcriptional analysis

Autor: Daniel G. Stover, Emily Schlosnagle, Beth Overmoyer, Amy C. Y. Lo, Beth T. Harrison, Nickles Dorothee, Justin M. Balko, Carmina Espiritu, Charles Havnar, Jennifer M. Giltnane, Sarajane Nghiem, Anneleen Daemen, Emmanuel Naouri

Publikováno v: Cancer Research. 80:P6-15

Introduction: Inflammatory breast cancer (IBC) is a clinical diagnosis that spans all breast cancer subtypes. The clinical course of IBC is associated with poorer outcomes than molecular subtype-matched non-IBC and represents an unmet need in breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd0d220d804677e22a7ae306e6a0e235
https://doi.org/10.1158/1538-7445.sabcs19-p6-15-02

Zobrazit plný text záznamu

Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade

Autor: H Parsons, Emily Schlosnagle, Jiani Hu, Grace Winship, Faina Nakhlis, Nicholas Johnson, Shom Goel, Meredith M. Regan, Beth T. Harrison, Jennifer L. Guerriero, Beth Overmoyer, Sonia Pernas, LA Chichester, Elizabeth A. Mittendorf

Publikováno v: Cancer Research. 79:PD3-08

Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that remains relatively understudied. We examined the efficacy of neoadjuvant dual-HER2 blockade (trastuzumab (H) and pertuzumab (P)) combined with paclitaxel (T) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ec72c8a09acd29b6a3feea52a224e9e
https://doi.org/10.1158/1538-7445.sabcs18-pd3-08

Zobrazit plný text záznamu

Abstract P6-09-10: Association of dermal lymphatic involvement and survival in inflammatory breast cancer

Autor: J Schlossman, Eren D. Yeh, Emily Schlosnagle, Beth Overmoyer, Kelly A. Hirko, Faina Nakhlis, Heather A. Jacene, Beth T. Harrison

Publikováno v: Cancer Research. 79:P6-09

Purpose: The pathologic hallmark of inflammatory breast cancer (IBC) is the presence of tumor emboli within the papillary and reticular dermis of the skin, termed dermal lymphatic invasion (DLI). DLI can be confirmed with a skin-punch biopsy in appro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c01f7d6fb2865db8f1e0ed3f28f4c514
https://doi.org/10.1158/1538-7445.sabcs18-p6-09-10

Zobrazit plný text záznamu

Abstract P6-15-11: Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer

Autor: Emily Schlosnagle, Laura S. Dominici, Faina Nakhlis, J Hirshfield-Bartek, Meredith M. Regan, Beth T. Harrison, AH Partridge, A Morikawa, Jennifer R. Bellon, Rachel A. Freedman, Nu Lin, Beth Overmoyer, EP Winer, DE Morganstern, Jiani Hu

Publikováno v: Cancer Research. 78:P6-15

Background: Inflammatory breast cancer (IBC) is inoperable at presentation, thus neoadjuvant systemic therapy (NAS) is the primary treatment for this aggressive disease. Due to its rarity, patients (pts) with IBC are incorporated into NAS clinical tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::729b5aabed2699000e41a8044a254632
https://doi.org/10.1158/1538-7445.sabcs17-p6-15-11

Zobrazit plný text záznamu

Abstract P6-12-12: Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)

Autor: Rachel A. Freedman, AH Partridge, Emily Schlosnagle, Sara M. Tolaney, Meredith M. Regan, Erica L. Mayer, Daniel P. Silver, Craig A. Bunnell, Wendy Y. Chen, Beth Overmoyer, EP Winer

Publikováno v: Cancer Research. 77:P6-12

This abstract was not presented at the symposium.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f32edc1eb23013791e427d840110dc2
https://doi.org/10.1158/1538-7445.sabcs16-p6-12-12

Zobrazit plný text záznamu

Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning

Autor: Faina Nakhlis, Eren D. Yeh, Jiani Hu, Su-Chun Cheng, Beth Overmoyer, Jennifer R. Bellon, Emily Schlosnagle, Pamela J. DiPiro, Laura E.G. Warren, Jennifer M. Rosenbluth, Heather A. Jacene

Publikováno v: Breast cancer research and treatment. 181(2)

Optimizing treatment strategies for patients with inflammatory breast cancer (IBC) relies on accurate initial staging. This study compared contrast-enhanced computed tomography (ce-CT) and FDG-PET/CT for initial staging of IBC to determine the freque

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ee08ed7235cf826ccc568319a8d9f7e
https://pubmed.ncbi.nlm.nih.gov/32318957

Zobrazit plný text záznamu

Prevalence of germline variants in inflammatory breast cancer

Autor: Rosalba Sacca, Holly LaDuca, Virginia Speare, Emily Schlosnagle, Judy Garber, Beth Overmoyer, Jill S. Dolinsky, Christine Drogan, Huma Q. Rana, Stephanie Gutierrez, Meredith M. Regan

Publikováno v: Cancer.

Background Inflammatory breast cancer (IBC) is an uncommon and aggressive subtype of breast cancer associated with early disease recurrence and short survival. The prevalence of germline variants in cancer predisposition genes has not been systematic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efeee7a031bcd8dd3ac5b6c5a4c1a8cf
https://doi.org/10.1002/cncr.32062

Zobrazit plný text záznamu

Abstract P6-18-03: Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine

Autor: Jennifer R. Bellon, Faina Nakhlis, Emily Schlosnagle, Aditi Hazra, Kelly A. Hirko, Eren D. Yeh, Laura S. Dominici, Beth Overmoyer, Heather A. Jacene, J Hirshfield-Bartek, Laura E.G. Warren

Publikováno v: Cancer Research. 76:P6-18

Introduction: Inflammatory breast cancer (IBC) is a rare and highly lethal form of breast cancer, accounting for approximately 10% of breast cancer mortality in the US. The clinical presentation of IBC includes rapid onset of symptoms, erythema > 1/3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ae1cb9c4d905529481df981f1cf81c9
https://doi.org/10.1158/1538-7445.sabcs15-p6-18-03

Zobrazit plný text záznamu

Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy

Autor: J Paolino, Eren D. Yeh, Shom Goel, Beth Overmoyer, Emily Schlosnagle, Faina Nakhlis, Amanda Abbott, A Culhane, A. D. Van Den Abbeele, J Hirshfield-Bartek, Heather A. Jacene, Jennifer R. Bellon

Publikováno v: Cancer Research. 77:OT2-02

Background: Inflammatory breast cancer (IBC) continues to have a poor prognosis despite standard tri-modality treatment with chemotherapy, mastectomy and radiation. Current methods of assessing primary tumor response (i.e., clinical exam and breast m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::47b3c879f01d6b88b94a35814f18e8a6
https://doi.org/10.1158/1538-7445.sabcs16-ot2-02-03

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání